Cardiocore Advances Holter Bin Method for ECGs
Enhanced level of QT analysis offers sponsors a more complete foundation to establish drug safety.
Washington, DC-Cardiocore, a centralized cardiac testing lab, announced today that it has accomplished significant advancements in the Holter Bin Methodology for ECG data analysis. Cardiocore’s technology and processes isolate heart rate-related QT effects, thereby reducing the potential for false positive outcomes in Thorough QT studies.
Cardiocore Chief Medical Officer, Lawrence Satin, MD, FACC has been invited to discuss these developments at the FDA’s Cardiovascular Safety, QT, and Arrhythmia in Drug Development conference, on April 29-30, in Bethesda, MD.
Dr. Satin’s presentation will demonstrate how the Holter Bin method highlights distinctions between various causes of QT prolongation. This enhanced level of QT analysis may be valuable to many Thorough QT study sponsors.
“We are very proud to provide our clients this advanced scientific service in their cardiac safety trials,” said Dr. Satin. He continued, “Particularly for drug developers who’s compound may affect heart rate, this methodology provides a clearer and more complete foundation to establish their drug’s safety profile.”
Cardiocore Vice President of Medical Operations, Polina Voloshko, MD added, “To properly apply the Holter Bin technique, important intricacies such as time-matching and hysteresis management must be addressed. Cardiocore has resolved these issues by deploying sophisticated technologies and by applying a full understanding of the test drug’s pharmacokinetic profile into the protocol design.”
In support of Cardiocore’s Holter Bin service, well-known cardiac testing technology provider, AMPS, has customized its newly upgraded WinAtrec application for seamless integration into Cardiocore’s advanced cardiac data management platform.
As a secondary endpoint in a Thorough QT study, this Holter Bin solution complements the mathematical formulas traditionally used to mitigate the affect of heart rate variability on QT analysis. Heart beats are organized into “bins” of similar heart rate. Measurements from one beat are compared to those from other beats within the same bin. The resulting data distinguishes potentially fatal forms of QT prolongation—those caused by ion channel blockade—from less-troubling types of QT prolongation caused by heart rate fluctuation.
More information about Cardiocore’s scientific expertise, data management system, and sponsor-benefiting Holter solutions are available at the company’s web site, http://www.cardiocare.com/
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
